Status:
ACTIVE_NOT_RECRUITING
A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment
Lead Sponsor:
Bayer
Conditions:
Metastatic Colorectal Cancer
Eligibility:
MALE
18+ years
Brief Summary
This is an observational study in which data already collected from people with metastatic colorectal cancer will be studied. Metastatic colorectal cancer (mCRC) is a cancer of the colon (large bowel...
Eligibility Criteria
Inclusion
- Aged ≥18 years at diagnosis of mCRC
- Histologically confirmed diagnosis of mCRC
- Received sequential treatment with regorafenib followed by TAS with or without Bevacizumab (R-TAS±BEV, without other therapies in-between) and vice versa (TAS±BEV -R without other therapies in-between) from January 1, 2013 to December 31, 2022 (inclusion period), or the latest available date that allows at least 3 months of follow-up
- Have at least 6 months of available data before index date (baseline period) and at least 3 months of follow-up data
Exclusion
- Patients who had a diagnosis of any other primary cancer (including gastrointestinal stromal tumors (GIST) and hepatocellular carcinoma (HCC)) except non-melanoma skin cancers during baseline
- Patients involved in clinical trials during the study period
Key Trial Info
Start Date :
March 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06137170
Start Date
March 1 2024
End Date
March 31 2025
Last Update
March 12 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations
Multiple Locations, France
2
Many Locations
Multiple Locations, Italy
3
Many Locations
Multiple Locations, Spain